A Study of Chlorhexidine in the Prevention of HIV-1 Transmission From Mothers to Their Babies
Information source: National Institute of Allergy and Infectious Diseases (NIAID)
ClinicalTrials.gov processed this data on August 23, 2015 Link to the current ClinicalTrials.gov record.
Condition(s) targeted: HIV Infections
Intervention: Chlorhexidine gluconate (Drug)
Phase: Phase 2
Status: Completed
Sponsored by: National Institute of Allergy and Infectious Diseases (NIAID) Official(s) and/or principal investigator(s): Craig Wilson, Study Chair Sten Vermund, Study Chair
Summary
The purpose of this study is to find the best strength of chlorhexidine (a solution that
kills germs), for washing the mother's vagina during labor and the newborn baby, that may
reduce the chance of HIV being passed from an HIV-positive mother to the baby.
When used as a wash on the vagina during labor, and on a newborn shortly after birth, a
higher dose of chlorhexidine is more likely to reduce the rate of HIV-1 transmission from
mother to baby. Laboratory tests suggest that a higher dose of chlorhexidine will be more
effective in killing HIV.
Clinical Details
Official title: Phase IIA Study of Tolerance and Safety of Differing Concentrations of Chlorhexidine, for Peripartum Vaginal and Infant Washes, to Prevent Mother to Infant HIV-1 Transmission
Study design: Primary Purpose: Prevention
Detailed description:
The principal hypothesis of this protocol is that, in the context of routine oral/nasal
suctioning of infants, a higher concentration of chlorhexidine for peripartum vaginal and
postpartum newborn cleansing results in reduction in maternal child transmission (MCT) of
HIV. The in vitro data suggest that a higher concentration of chlorhexidine in the primary
wash solution is much more likely to have a virucidal effect perinatally and thus reduce
MCT.
Perinatal intervention consists of the following: 1) cervicovaginal wash of the entire birth
canal with a chlorhexidine solution at the time of each vaginal examination of a mother in
labor; 2) immediate suctioning of the nasal and oral passages of the infant at the time the
head emerges (fluids to be tested for viral load at future date); and 3) thorough washing of
the baby with a chlorhexidine solution immediately after delivery. Blood samples are
collected from some infants for measurement of chlorhexidine levels approximately 2 hours
post-washing. During the 24 to 48 hours following delivery, infants are examined and mothers
are queried using standardized questionnaires for subjective complaints related to the
chlorhexidine washes. Speculum-aided vaginal exams are done for any persistent (greater than
24 hours) or severe complaints.
Eligibility
Minimum age: N/A.
Maximum age: N/A.
Gender(s): Both.
Criteria:
Inclusion Criteria
Mothers may be eligible for this study if they:
- Receive HIV testing and counseling (both HIV-positive and HIV-negative women will be
enrolled).
- Are at least 36 weeks pregnant.
- Are receiving routine prenatal care at the Chris Hani Baragwanath Hospital maternity
unit in Soweto, South Africa.
Exclusion Criteria
Mothers will not be eligible if they:
- Have severe complications during the pregnancy, such as bleeding before birth.
- Have a C-section by choice.
- Have obvious genital sores at the time of labor.
- Have a baby that is positioned a certain way during delivery.
- Receive prostaglandin tablets, in the vagina, during labor.
- Have major medical conditions, such as TB or diabetes (except HIV, in HIV-positive
women).
Locations and Contacts
Ann Koonce, Research Triangle Park, North Carolina 27709, United States
Additional Information
Haga clic aquí para ver información sobre este ensayo clínico en español.
Related publications: Wilson CM, Gray G, Read JS, Mwatha A, Lala S, Johnson S, Violari A, Sibiya PM, Fleming TR, Koonce A, Vermund SH, McIntyre J. Tolerance and safety of different concentrations of chlorhexidine for peripartum vaginal and infant washes: HIVNET 025. J Acquir Immune Defic Syndr. 2004 Feb 1;35(2):138-43.
Last updated: September 26, 2008
|